Armata Pharmaceuticals, Inc. (ARMP)
3.135
+0.08
(+2.45%)
USD |
NYAM |
Oct 22, 10:11
Armata Pharmaceuticals Enterprise Value : 403.67M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 403.67M |
| October 20, 2026 | 408.87M |
| October 19, 2026 | 404.04M |
| October 16, 2026 | 415.18M |
| October 15, 2026 | 404.78M |
| October 14, 2026 | 393.27M |
| October 13, 2026 | 405.15M |
| October 12, 2026 | 424.84M |
| October 09, 2026 | 424.84M |
| October 08, 2026 | 433.38M |
| October 07, 2026 | 431.53M |
| October 06, 2026 | 433.01M |
| October 05, 2026 | 425.95M |
| October 02, 2026 | 420.75M |
| October 01, 2026 | 412.95M |
| September 30, 2026 | 426.33M |
| September 29, 2026 | 423.35M |
| September 28, 2026 | 430.41M |
| September 25, 2026 | 428.93M |
| September 24, 2026 | 424.47M |
| September 23, 2026 | 425.21M |
| September 22, 2026 | 446.01M |
| September 21, 2026 | 448.24M |
| September 18, 2026 | 445.27M |
| September 17, 2026 | 442.30M |
| Date | Value |
|---|---|
| September 16, 2026 | 441.18M |
| September 15, 2026 | 453.44M |
| September 14, 2026 | 496.16M |
| September 11, 2026 | 489.84M |
| September 10, 2026 | 484.27M |
| September 09, 2026 | 490.96M |
| September 08, 2026 | 506.19M |
| September 04, 2026 | 506.93M |
| September 03, 2026 | 495.05M |
| September 02, 2026 | 495.42M |
| September 01, 2026 | 486.13M |
| August 31, 2026 | 494.67M |
| August 28, 2026 | 489.47M |
| August 27, 2026 | 491.70M |
| August 26, 2026 | 492.45M |
| August 25, 2026 | 496.53M |
| August 24, 2026 | 482.04M |
| August 21, 2026 | 479.44M |
| August 20, 2026 | 454.18M |
| August 19, 2026 | 478.33M |
| August 18, 2026 | 459.39M |
| August 17, 2026 | 456.41M |
| August 14, 2026 | 459.39M |
| August 13, 2026 | 469.04M |
| August 12, 2026 | 450.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 537.40M |
| Amgen, Inc. | 280.28B |
| Anika Therapeutics, Inc. | 262.53M |
| BioCryst Pharmaceuticals, Inc. | 2.462B |
| Imunon, Inc. | 6.533M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 74.14M |
| Revenue (Quarterly) | 2.51M |
| Total Expenses (Quarterly) | -71.63M |
| EPS Diluted (Quarterly) | -0.272 |
| Gross Profit Margin (Quarterly) | 76.45% |
| Earnings Yield | -242.0% |
| Normalized Earnings Yield | -135.63 |